Fluticasone furoate liposome suspension and preparation method thereof

A technology of fluticasone furoate resin and fluticasone furoate, which is applied in liposome delivery, pharmaceutical formula, liquid delivery, etc., can solve problems such as limitations, achieve high encapsulation efficiency, simple production process, and good repeatability

Active Publication Date: 2020-10-20
SHANGHAI ANOVENT PHARMA CO LTD
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, in clinical practice, nebulizers are widely used in the inhalation administration of water-s

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fluticasone furoate liposome suspension and preparation method thereof
  • Fluticasone furoate liposome suspension and preparation method thereof
  • Fluticasone furoate liposome suspension and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Preparation of 10ml liposomes

[0032] Total initial volume = 100ml,

[0033] Ethanol content 30%, lipid composition: DPPC / cholesterol (molar ratio is 1: 1),

[0034] Initial lipid = 0.3 mg / ml, initial fluticasone furoate = 0.01 mg / ml,

[0035] Volume of final product = 10ml,

[0036] Step (1) mix and inject:

[0037] Dissolve 19.6mg of DPPC and 10.4mg of cholesterol directly in 30ml of ethanol in a water bath at 50°C, and then add 1mg of fluticasone furoate to completely dissolve it. Slowly inject the above-mentioned ethanol solution into 50ml of physiological saline under stirring state, and after mixing for 20 minutes, dilute to 100ml with physiological saline to obtain an initial volume of 100ml.

[0038] Step (2) diafiltration concentration step:

[0039] Hook the mixing container onto the peristaltic pump and diafilter cartridge. Diafilter cartridges are concave membrane fibers with a molecular weight cut off of 500,000 Daltons. The product was pumped from ...

Embodiment 2

[0041] Preparation of 10ml liposomes

[0042] Total initial volume = 100ml, ethanol content 30%,

[0043] Lipid composition: DPPC / ergosterol (molar ratio is 1:1), initial lipid=0.2mg / ml,

[0044] Initial fluticasone furoate = 0.01 mg / ml, final product volume = 10 ml,

[0045] Step (1) mix and inject:

[0046] Dissolve 19.6mg of DPPC and 10.4mg of ergosterol directly in 30ml of ethanol in a water bath at 50°C, and then add 1mg of fluticasone furoate to completely dissolve it. Slowly inject the above-mentioned ethanol solution into 50ml of physiological saline under stirring state, and after mixing for 20 minutes, dilute to 100ml with physiological saline to obtain an initial volume of 100ml.

[0047] Step (2) diafiltration concentration step:

[0048] Hook the mixing container onto the peristaltic pump and diafilter cartridge. Diafiltration cartridges are concave membrane fibers with a molecular weight cut off of 500,000 Daltons. The product was pumped from the reaction v...

Embodiment 3

[0050] Fluticasone furoate liposomes with high encapsulation efficiency

[0051] According to the following steps, 5 parts of liposome suspensions with different drug and lipid ratios and high encapsulation efficiency were prepared. The encapsulation efficiency of 5 samples was all above 80%, and the encapsulation efficiency of sample 5 The rate is above 90%, and the average particle size is between 130nm and 160nm.

[0052]Sample #1: Weigh 6.5mg of DPPC and 3.5mg of cholesterol in a beaker, add 30ml of ethanol in a water bath at 50°C to dissolve completely, then add 1mg of FF to dissolve completely. While stirring, slowly drop the above solution into 50ml of normal saline with a syringe, mix for 20 minutes, and then dilute to 100ml with normal saline. The product was passed through a hollow fiber membrane at room temperature to remove ethanol and free fluticasone furoate and concentrated to 10 ml.

[0053] Sample #2: Weigh 9.8mg of DPPC and 5.2mg of cholesterol in a beaker,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
The average particle sizeaaaaaaaaaa
Molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention provides a fluticasone furoate liposome and a preparation method thereof. The fluticasone furoate liposome comprises the components of phospholipid, sterol and fluticasone furoate, wherein the fluticasone furoate accounts for 0.01%-1%, the phospholipid accounts for 0.065%-0.196%, and the sterol accounts for 0.035%-0.104%. A preparation method of the fluticasone furoate liposome comprises the steps of (1) performing mixing and injecting; and (2) performing filtering and concentrating. The method is simple to operate, stable in technology and suitable for mass production.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, in particular to fluticasone furoate liposome suspension and a preparation method thereof. Background technique [0002] Certain sustained-release technologies suitable for inhaled administration use liposomes and lipoplexes to provide prolonged drug therapy to the lungs and systemically through sustained release and targeting capabilities and enhanced drug absorption at the site of disease. The invention comprises a method for treating lung diseases with liposome fluticasone furoate inhalation suspension. [0003] For drugs that are easily destroyed in the gastrointestinal tract or cannot be taken orally, inhalation is a better way of administration than injection. The bioavailability of the hormone drug system is low, and administration through the inhalation route can overcome the shortcomings of oral administration or intravenous injection of hormone therapy, especially t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/127A61K9/10A61K9/72A61K47/24A61K47/28A61K31/58A61P11/00
CPCA61K9/0078A61K9/10A61K9/127A61K31/58A61K47/24A61K47/28A61P11/00
Inventor 黄才古许英爱范晨梦
Owner SHANGHAI ANOVENT PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap